Transaction #33455 · Form 4 · 0001493152-26-047058
Akari Therapeutics Plc · Stock award · Stock Option (Right to Buy)
Akari Therapeutics Plc · Transacted October 12, 2026 · Filed October 14, 2026
What does this filing report?
An SEC Form 4 filing for Akari Therapeutics Plc records a stock award involving Stock Option (Right to Buy) on October 12, 2026. The reported quantity was 87,000. The filing date is October 14, 2026. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Akari Therapeutics Plc
- Company CIK
- 0001541157
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 87,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 87,000
- Ownership description
- Not reported
- SEC acceptance time
- Oct 14, 2026, 5:21 PM EDT
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Vat-Ho Vatnak ↗
Chief Business Officer
CIK 0002160022
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- American Depositary Shares representing Ordinary Shares
- Underlying quantity
- 87,000
- Conversion / exercise price
- 8.94
- Exercise date
- Not reported
- Expiration date
- October 5, 2036
Filing footnotes & remarks
- F1
- On October 5, 2026 (the "Grant Date"), the reporting person was granted an option to purchase 87,000 ADSs. This option grant is subject to forfeiture and cancellation if shareholder approval of a proposed amendment to the Issuer's equity incentive plan to increase the number of shares reserved for issuance under the plan is not obtained. The option will vest with respect to 25% on the 12-month anniversary of the Grant Date, with the remainder vesting in equal monthly installments over the next 36 months until fully vested on the 4-year anniversary of the Grant Date, subject to the grantee's continued service with the Company.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.